Saturday - May 3, 2025
NEW YORK, June 05, 2023 (GLOBE NEWSWIRE) -- Talkspace (Nasdaq: TALK), a leading behavioral healthcare company, today announced that Dr. Jon Cohen, Chief Executive Officer, and Jennifer Fulk, Chief Financial Officer, will participate at the Truist Securities 2023 Healthcare Disruptors & Digital Health Summit, including a panel titled, “Addressing the Mental Health Crisis,” beginning at 10:30am ET on June 21, 2023.
About Talkspace
Talkspace (NASDAQ: TALK) is a leading virtual behavioral healthcare company committed to helping people lead healthier, happier lives through access to high-quality mental healthcare. At Talkspace, we believe that mental healthcare is core to overall health and should be available to everyone.
Talkspace pioneered the ability to text with a licensed therapist from anywhere and now offers a comprehensive suite of mental health services from self-guided products to individual and couples therapy, in addition to psychiatric treatment and medication management. With Talkspace’s core psychotherapy offering, members are matched with one of thousands of licensed providers across all 50 states and can choose from a variety of subscription plans including live video, text or audio chat sessions and/or unlimited, asynchronous text messaging.
All care offered at Talkspace is delivered through an easy-to-use, fully-encrypted web and mobile platform that meets HIPAA, federal, and state regulatory requirements. Talkspace covered approximately 112 million lives as of May 2, 2023, through our partnerships with employers, health plans, and paid benefits programs.
For more information, visit www.talkspace.com.
Contacts
For Investors:
Sloane & Co.
Neal Nagarajan
(301) 273-5662
nnagarajan@sloanepr.com
For Media:
SKDK
John Kim
(310) 997-5963
jkim@skdknick.com
Last Trade: | US$3.19 |
Daily Change: | 0.06 1.92 |
Daily Volume: | 1,875,144 |
Market Cap: | US$538.850M |
February 20, 2025 December 10, 2024 October 29, 2024 September 04, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load